Fresenius Kabi has launched its denosumab biosimilars Conexxence® and Bomyntra® across Europe following European Commission approval in July 2025 for all indications of their reference medicines ...
RNA, widely known from the COVID-19 vaccine, is not actually a "therapeutic agent," but a technology that delivers the blueprint for functional ...
Disease development is often shaped by genetics, with how much or how little a gene is expressed influencing disease risk.
Regeneron Pharmaceuticals has teamed up with Tessera Therapeutics to develop and commercialise Tessera’s rare disease in vivo ...
Researchers at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust have developed AI software that automates the complex interpretation of whole-body diffusion-weighted MRI ...
The DTC Genetic Testing Market is poised for growth, driven by rising health awareness and demand for personalized insights.
SGT-212 has been granted FDA Rare Pediatric Disease and Fast Track designations –– SGT-212 is the only dual route gene therapy in development ...
Pharmaceutical Technology on MSN
Potentially “groundbreaking” FDA gene therapy pathway leaves key issues unresolved
A new FDA pathway could speed bespoke gene therapies, but key questions over scope and commercial viability remain.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback